Related Experiment Video
Updated: Jul 10, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library
Qiong Zhang1, Yi Liu, Feng Gao
1Departments of Chemistry and Cell Biology, Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA.
Abstract:
The epidermal growth factor receptor (EGFR) tyrosine kinase was one of the first receptor tyrosine kinases to be targeted for drug development by the pharmaceutical industry due to its ubiquitous overexpression in a variety of tumors. Despite the validation of several quinazoline-based scaffolds in the clinic, there is a dearth of alternative chemical structure classes that are capable of inhibiting EGFR kinase activity selectively. Here we describe the discovery of potent and highly selective 4,6-disubstituted pyrimidine inhibitors of enzymatic and cellular EGFR activity and provide an explanation for their exceptional degree of kinase selectivity.
Insights
Researchers discovered new pyrimidine-based drugs that selectively inhibit epidermal growth factor receptor (EGFR) tyrosine kinase. These compounds offer a promising alternative to existing quinazoline drugs for cancer therapy.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase is a key target in cancer drug development due to its overexpression in various tumors.
- Existing EGFR inhibitors, primarily quinazoline-based, face limitations, highlighting the need for alternative chemical scaffolds.
- Selective inhibition of EGFR kinase activity is crucial to minimize off-target effects and improve therapeutic outcomes.
Purpose of the Study:
- To discover novel chemical classes of potent and selective EGFR kinase inhibitors.
- To explore 4,6-disubstituted pyrimidine derivatives as potential therapeutic agents against EGFR-driven cancers.
- To elucidate the structural basis for the observed selectivity of these pyrimidine inhibitors.
Main Methods:
- Design and synthesis of a library of 4,6-disubstituted pyrimidine compounds.
- In vitro enzymatic assays to evaluate inhibitory potency against EGFR kinase.
- Cellular assays to assess the inhibition of EGFR signaling pathways and cellular proliferation.
- Structure-activity relationship (SAR) studies and computational modeling to understand selectivity.
Main Results:
- Identification of potent 4,6-disubstituted pyrimidine inhibitors demonstrating significant enzymatic and cellular activity against EGFR.
- Demonstration of high selectivity for EGFR over other related kinases, suggesting a reduced potential for off-target toxicity.
- Elucidation of key structural features contributing to the selective binding and inhibition of the EGFR kinase domain.
Conclusions:
- 4,6-disubstituted pyrimidines represent a novel and effective chemical scaffold for the development of selective EGFR inhibitors.
- These findings provide a promising alternative to current therapies and warrant further investigation for clinical application in cancer treatment.
- The detailed understanding of selectivity mechanisms can guide the design of next-generation kinase inhibitors.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase